These observations, together with reports on the effectiveness of mAbs-mediated passive immunotherapy against HER2, suggest that the stimulation of anti-HER2 immune response via vaccination can be used for the treatment of HER2-positive cancers or to prevent disease recurrence [100,109,110]. Here, ERBB2 is linked to cancer.